Lineage Cell Therapeutics(LCTX) - 2025 Q1 - Quarterly Results

LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE CARLSBAD, CA – May 13, 2025 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical- stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today reported its first quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and ...